The Role of FoxC2 Transcription Factor in Tumor Angiogenesis
Much has been learned about the mechanisms underlying tumor angiogenesis, and therapies that target vascular endothelial growth factor (VEGF) to limit tumor angiogenesis and subsequent disease progression have recently been approved. However, the transcriptional mechanisms that regulate pathological...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228356/ |
| id |
pubmed-3228356 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-32283562011-12-15 The Role of FoxC2 Transcription Factor in Tumor Angiogenesis Kume, Tsutomu Review Article Much has been learned about the mechanisms underlying tumor angiogenesis, and therapies that target vascular endothelial growth factor (VEGF) to limit tumor angiogenesis and subsequent disease progression have recently been approved. However, the transcriptional mechanisms that regulate pathological angiogenesis remain largely unknown. FoxC2, a member of the Forkhead box (Fox) transcription factor family, is critical for vascular formation during development, and recent studies have shown that FoxC2 is expressed in the endothelium of tumors in both humans and mice. In a B16 mouse melanoma model, Foxc2 deficiency reduced tumor growth and neovascularization and was associated with impairments in mural-cell coverage and increases in endothelial-cell apoptosis in tumor blood vessels. FoxC2 is also expressed by tumor cells in human breast, colonic, and esophageal cancer and participates in the epithelial-mesenchymal transition (EMT), a key process that leads to the invasion and metastasis of aggressive tumors. Collectively, these observations suggest that FoxC2 is essential for tumor angiogenesis and disease progression and that FoxC2 may be a viable target for cancer therapy. Hindawi Publishing Corporation 2012 2011-11-16 /pmc/articles/PMC3228356/ /pubmed/22174714 http://dx.doi.org/10.1155/2012/204593 Text en Copyright © 2012 Tsutomu Kume. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Kume, Tsutomu |
| spellingShingle |
Kume, Tsutomu The Role of FoxC2 Transcription Factor in Tumor Angiogenesis |
| author_facet |
Kume, Tsutomu |
| author_sort |
Kume, Tsutomu |
| title |
The Role of FoxC2 Transcription Factor in Tumor Angiogenesis |
| title_short |
The Role of FoxC2 Transcription Factor in Tumor Angiogenesis |
| title_full |
The Role of FoxC2 Transcription Factor in Tumor Angiogenesis |
| title_fullStr |
The Role of FoxC2 Transcription Factor in Tumor Angiogenesis |
| title_full_unstemmed |
The Role of FoxC2 Transcription Factor in Tumor Angiogenesis |
| title_sort |
role of foxc2 transcription factor in tumor angiogenesis |
| description |
Much has been learned about the mechanisms underlying tumor angiogenesis, and therapies that target vascular endothelial growth factor (VEGF) to limit tumor angiogenesis and subsequent disease progression have recently been approved. However, the transcriptional mechanisms that regulate pathological angiogenesis remain largely unknown. FoxC2, a member of the Forkhead box (Fox) transcription factor family, is critical for vascular formation during development, and recent studies have shown that FoxC2 is expressed in the endothelium of tumors in both humans and mice. In a B16 mouse melanoma model, Foxc2 deficiency reduced tumor growth and neovascularization and was associated with impairments in mural-cell coverage and increases in endothelial-cell apoptosis in tumor blood vessels. FoxC2 is also expressed by tumor cells in human breast, colonic, and esophageal cancer and participates in the epithelial-mesenchymal transition (EMT), a key process that leads to the invasion and metastasis of aggressive tumors. Collectively, these observations suggest that FoxC2 is essential for tumor angiogenesis and disease progression and that FoxC2 may be a viable target for cancer therapy. |
| publisher |
Hindawi Publishing Corporation |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228356/ |
| _version_ |
1611491174635274240 |